FDA Orthopedic Implant Recalls: Zimmer Biomet Leads 3,167 Hip & Knee Recall Records

Executive Summary

Total hip, knee, and shoulder replacement is one of the highest-volume implant categories in medicine, yet the post-market record shows a recall system dominated by a handful of manufacturers. Our analysis of FDA recall and enforcement records tied to joint-replacement product codes finds a concentrated, packaging- and manufacturing-heavy recall landscape:

• 3,167 joint-replacement recall records map to 70 distinct FDA product codes for hip, knee, shoulder, and elbow prostheses — with knee (1,401) and hip (1,396) devices driving roughly 89% of the activity.
• Zimmer Biomet alone accounts for 1,162 of those records — about 37% of all joint-implant recalls — and the top 10 recalling firms together drive 86.9% of the total. Stryker (514) and DePuy Synthes / Johnson & Johnson (319) round out the top three.
• 96% of joint-replacement enforcement actions are Class II, and the devices entered the market almost entirely through the 510(k) pathway (4,580 510(k) clearances versus just 13 PMA records for the same product codes) — a regulatory structure most patients and many clinicians do not realize governs permanent implants.
• Manufacturing, material, and design issues (32%) and packaging / labeling (28%) are the leading root-cause buckets, a profile the Exactech polyethylene-oxidation recall made infamous.

The implication for regulatory, quality, and supply-chain professionals is direct: when a joint-implant recall happens, it is overwhelmingly traceable to a small set of legacy Class II predicates owned by a small set of firms, and the dominant failure modes are manufacturing-process and packaging defects rather than novel technology failures.

The Regulatory Paradox: Permanent Implants, Class II Review

A common assumption is that anything permanently implanted in the body is a high-risk Class III device requiring a Premarket Approval (PMA). For conventional hip, knee, and shoulder replacements, that assumption is wrong. The FDA regulates most total-joint prostheses as Class II devices under 21 CFR Part 888, cleared through the 510(k) premarket-notification process against one or more legally marketed "predicate" devices rather than through the more rigorous PMA route that demands clinical data.

Our data confirms this directly. For the 70 joint-replacement product codes in this analysis:

In other words, for every PMA record tied to these implant codes, there are roughly 350 510(k) clearances. This matters because the 510(k) standard is "substantial equivalence" to a predicate — not an independent demonstration of safety and effectiveness. The recall record is, in part, a downstream signal of how that predicate-based system performs when a design is iterated across decades and manufacturers.

Data Source and Method

• Device universe: 70 FDA product codes flagged as hip, knee, shoulder, or elbow joint-prosthesis devices in the FDA device-classification table (medical specialty = Orthopedic). Examples include JWH (patellofemorotibial knee prosthesis), LPH/JDI (metal/polymer hip prosthesis), and KWS (shoulder prosthesis).
• Analysis sample: 3,167 records from the FDA Medical Device Recall database keyed to those 70 product codes; 3,002 device-enforcement-report records identified by text matching of the product-description and reason-for-recall fields against joint-replacement terminology; 4,580 510(k) clearances and 13 PMA records under the same codes.
• Method: All counts were computed by MedDeviceGuide from public FDA extracts. Recalling-firm names were consolidated across corporate variants (for example, "Zimmer Inc.," "Zimmer, Inc.," "Biomet, Inc.," and "Zimmer Biomet" were grouped under Zimmer Biomet; "DePuy," "DePuy Orthopaedics," and Johnson & Johnson DePuy entities under DePuy Synthes). The FDA enforcement database does not carry a populated product-code field, so enforcement records were identified by text matching and firm counts there are approximate. Root-cause themes are derived from FDA reason-for-recall text and are mutually exclusive at the top level.

Recall Concentration: A Handful of Firms Carry the Burden

The single most striking feature of the joint-implant recall record is how concentrated it is. Across 3,167 recall records, the top recalling firms are:

The top-10 firms collectively account for 86.9% of all joint-replacement recall records. This mirrors the upstream clearance market: the same firms that clear the most joint-implant 510(k)s — Zimmer Biomet (672), Stryker (554), DePuy Synthes (373), Smith & Nephew (228) — also appear most frequently on the recall side. The recall burden is, in effect, a concentrated function of a concentrated market.

The Exactech Episode: When Packaging Becomes a Device Defect

The clearest illustration of how manufacturing and packaging failures drive joint-implant recalls is Exactech. Beginning August 2021, Exactech recalled polyethylene inserts used in its knee and ankle replacements after discovering that the plastic components had been packaged in vacuum bags missing a secondary oxygen-barrier layer of ethylene vinyl alcohol (EVOH). Without that barrier, oxygen could diffuse into the ultra-high-molecular-weight polyethylene (UHMWPE) insert during storage, causing oxidation that weakened the plastic and led to accelerated wear, bone loss, and early revision surgery.

The recall expanded repeatedly — to all knee and ankle polyethylene inserts in February 2022, to Connexion GXL hip liners in mid-2022, to shoulder components in March 2024, to patella components in April 2024, and to additional hip implants in December 2024 — ultimately covering more than 270,000 implants. In October 2024, Exactech filed for Chapter 11 bankruptcy amid multidistrict litigation (MDL 3044) that had grown to roughly 1,770 pending cases by late 2024.

Two facts make Exactech emblematic of the broader pattern. First, its devices were 510(k)-cleared Class II implants — the same regulatory tier as most of the joints in this analysis. Second, the failure mode (packaging → oxidation → material degradation) sits squarely in the two largest root-cause buckets below. A packaging process decision, repeated for years across a product family, became the central device-safety event.

Root Causes: Manufacturing and Packaging Dominate

Tallying the reason-for-recall text across the 3,167 recall records produces a clear hierarchy of why joint implants are recalled:

Manufacturing, material, and design issues lead, followed closely by packaging and labeling — the exact failure mode that drove the Exactech recall. Notably, software is essentially absent from joint-implant recalls, which distinguishes this category from connected or software-driven devices where firmware is a primary recall driver. The dominant risks are physical: out-of-specification machining, dimensional nonconformances, mislabeled components, and packaging that fails to protect the implant from oxidation or contamination.

Device Split and the Most-Recalled Codes

Joint-implant recall activity is split between knee and hip devices, with shoulder and elbow a distant third and fourth:

The single most-recalled product code is JWH (semi-constrained patellofemorotibial knee prosthesis), with 980 recall records — nearly three of every ten joint-implant recall records in the dataset. The next most-recalled codes are hip prostheses: LPH (metal/polymer porous, 297), JDI (metal/polymer cemented, 255), KWA (uncemented acetabular, 203), and MEH (uncemented metal/polymer, 196). The concentration in a handful of codes reinforces that recalls cluster around specific long-running predicate families rather than spreading evenly across the category.

Class Profile: Overwhelmingly Class II

Among the 3,002 joint-replacement enforcement-report records with an assigned classification:

Only 1.9% of joint-implant enforcement actions reach Class I (the level indicating a reasonable probability of serious adverse health consequences or death). This is consistent with the devices' Class II regulatory status: most recalls are corrections of manufacturing or packaging nonconformances that pose a use-related or longer-term reliability risk rather than an immediate life-threatening hazard. The low Class I share does not mean the consequences are trivial — revision surgery is a major intervention — but it does mean the recall system treats most joint-implant actions as moderate-risk events handled through correction and notification rather than market withdrawal.

Year-Over-Year Recall Activity

Recall initiation has been volatile rather than monotonic. By initiation year, the last decade shows periodic spikes:

The 2023 spike (213 records) reflects in part the maturation of the Exactech recall expansions and related polyethylene-insert corrections across multiple firms. The general decline into 2025 should be read cautiously: 2025-2026 data is still being populated in the FDA database, and recall initiation lags reporting.

What This Means for Quality, Regulatory, and Supply-Chain Teams

For manufacturers, the dataset carries three operational lessons:

1. Process and packaging controls are the primary recall risk for joint implants. Investments in design controls matter, but the dominant root-cause buckets — manufacturing/material/design and packaging/labeling — point to production process validation, change control, and packaging barrier qualification as the highest-leverage areas for recall prevention. The Exactech episode shows how a single packaging specification decision, left uncorrected for years, can become a company-ending event.
2. Predicate carry-forward concentrates risk. Because joint implants are 510(k) Class II devices cleared against predicates, manufacturing nonconformances and design assumptions propagate across model families and across firms. A post-market surveillance strategy that monitors a single predicate family can surface emerging issues before they reach recall scale.
3. Supplier and hospital due diligence should weight recall history. For group purchasing organizations, hospital value-analysis committees, and insurers, the recall concentration is actionable: a small number of firms account for the large majority of joint-implant recalls, and recall frequency (not just the existence of any recall) is a meaningful signal of manufacturing-process maturity. Contract terms, warranty provisions, and consignment-inventory controls can be calibrated accordingly.

For regulatory affairs teams preparing 510(k) submissions in this space, the data underscores that the bar is substantial equivalence to a predicate — and that the post-market record for those predicates is publicly auditable. Reviewing the recall history of the specific predicate family you intend to claim is now standard pre-submission diligence.

Data sources: FDA Medical Device Recall database, FDA device enforcement report database, FDA 510(k) and PMA databases, and the FDA device-classification table; analysis by MedDeviceGuide, run date 2026-06-16. Enforcement records were identified by text matching because the FDA enforcement database does not carry a populated product-code field; firm names were consolidated across corporate variants. Root-cause themes are derived from FDA reason-for-recall text. This article is educational and is not regulatory, quality-system, legal, or clinical advice for a specific product or company.